ERBB2 and non-small cell lung carcinoma: Since its initial approval as first-line treatment in metastatic CRC in 2004, bevacizumab has been approved for use in combination with other chemotherapeutics in four other tumor types: in 2009 (US) and 2007 (EU) for advanced RCC, in 2008 for metastatic HER2-negative BC, in 2009 for glioblastoma, and in 2004 for non-small cell lung cancer (NSCLC) [147–150].